Phase I/II study of the EP4 antagonist vorbipiprant combined with anti-PD-1 immunotherapy: safety and efficacy results in metastatic gastrointestinal non-colorectal cancers

Filippo Pietrantonio¹, Giovanni Randon¹, Chiara Carlotta Pircher¹, Filippo Ghelardi¹, Carolina Sciortino¹, Sara Alessandrini¹, Michele Palazzo¹, Nadia Brambilla², Giampaolo Giacovelli², Marta Monteforte², Federica Girolami², Lucio C Rovati^{2,3}

¹Department of Medical Oncology, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy; ³University of Milano Bicocca, School of Medicine, Milan, Italy

Background

- Novel combination strategies are being explored to enhance the effectiveness of immune checkpoint inhibitors (ICIs).
- Prostaglandin E2, through its receptor 4 (EP4), is a major contributor to immunosuppression in the tumor microenvironment.
- Vorbipiprant (CR6086), acting as EP4 antagonist, is supposed to restore the cancer-immunity cycle, enhancing ICI efficacy in immuneexcluded tumors [1,2].
- In the concluded dose-response part of this phase I/II study (NCT05205330), vorbipiprant combined PD-1 blockade with (balstilimab, Agenus, Inc.) was well tolerated and showed promising efficacy in refractory mismatch-repair-proficient/microsatellite stable (pMMR/MSS) metastatic colorectal cancer (mCRC) [3].
- The study was extended to non-colorectal metastatic gastrointestinal (GI) cancers, to explore the combination further potential activity.

Methods

- This was a phase lb/lla prospective, open label, single-arm trial conducted at one site in Italy.
- Adult patients (pts) with non-colorectal metastatic gastrointestinal (GI) cancers, ECOG PS ≤1 and failure of at least one prior treatment, were to be included in 3 cohorts (9 pts each): gastric cancer (GC) with PD-L1 Combined Positive Score (CPS) ≥5 (cohort A), GC with PD-L1 CPS<5 (cohort B), and GI cancers other than CRC and GC (cohort C). Pts received oral vorbipiprant (90 mg twice daily) plus iv balstilimab (3 mg/kg every 2 weeks) until disease progression, unacceptable toxicity or death.
- Primary endpoints were safety and disease control rate (DCR) per RECIST 1.1, analysed when all pts completed 24 weeks or were prematurely withdrawn.
- A 15% DCR associated with an acceptable safety profile in patients with gastric cancer, was considered a result meeting the primary endpoint; no predefined endpoint was foreseen for non-colorectal/nongastric GI cancer patients.
- Secondary endpoints included objective response rate (ORR), duration of response, progression-free and overall survival (PFS, OS). Exploratory endpoints include tissue and blood biomarkers.

References

- I] Take et al. Prostaglandin E Receptor 4 Antagonist in Cancer Immunotherapy: Mechanisms of Action. Front Immunol. 2020. 11:324
- 2] Bonavita et al. Antagonistic inflammatory phenotypes dictate tumor fate and response to immune checkpoint blockade. Immunity 2020; 53: 1-15
- 3] Pietrantonio et al. The Prostaglandin EP4 Antagonist Vorbipiprant Combined with PD-1 Blockade for Refractory Microsatellite-Stable Metastatic Colorectal Cancer: A Phase Ib/IIa Trial. Clin Cancer Res 2025;31:649-58

Conclusions Vorbipiprant combined with PD-1 blockade was well tolerated and showed signs of activity, on top of the results obtained in MSS mCRC. To further confirm preliminary positive results, a Phase II expansion in both MSS mCRC and GC patients is planned.

Poster presented at ASCO 2025 Congress – Chicago

Results

ble	1.	Baseline	chara	acteristics	
				Cohort A	Co

	Cohort A mGC PDL-1 CPS ≥5 (n=9)	Cohort B mGC PDL-1 CPS <5 (n=9)	Cohort C mBiliary/pancreatic cancer (N=9)	Overall (N=27)
e, median (range)	61 (57-64)	57 (55-65)	65 (61-74)	61 (55-68)
x M/F, n (%)	8 (89%)	6 (67%)	5 (56%)	19 (70%)
OG PS at baseline, n (%)				
)	4 (44%)	5 (56%)	3 (33%)	12 (44%)
	5 (56%)	4 (44%)	6 (67%)	15 (56%)
mary tumor site, n (%)				
Stomach	3 (33%)	5 (56%)	-	-
GEJ	6 (67%)	4 (44%)	-	-
Pancreas	-	-	2 (22%)	-
Biliary tract	-	-	5 (56%)	-
Vater ampulla	-	-	2 (22%)	-
nber of metastatic sites, n (%)				
1	4 (44%)	3 (33%)	4 (44%)	11 (41%)
≥ 2	5 (56%)	6 (67%)	5 (56%)	16 (59%)
of metastases, n (%)				
Liver	5 (56%)	6 (67%)	5 (56%)	16 (59%)
Limphonode	8 (89%)	4 (44%)	3 (33%)	15 (56%)
Peritoneum	2 (22%)	3 (33%)	4 (44%)	9 (33%)
Lung	2 (22%)	1 (11%)	4 (44%)	7 (26%)
Bone	0	2 (22%)	0	2 (7%)
Pleura	0	0	1 (11%)	1 (4%)
or lines, median (range)	3 (2-4)	3 (2-3)	2 (2-3)	3 (2-4)
or immunotherapy, n (%)	4 (44%)	2 (22%)	1 (11%)	7 (26%)
/MMR Status, n (%)				
MSS/pMMR	5 (56%)	6 (67%)	6 (67%)	17 (63%)
MSI/dMMR	2 (22%)	0	2 (22%)	4 (14%)
Jnknown	2 (22%)	3 (33%)	1 (11%)	6 (22%)

Safety

- Study drugs very well tolerated.
- No vorbipiprant-related AE grade \geq 3.
- 5 pts had SAE, all not related to study drugs, but 1 immunemediated pneumonitis related to balstilimab.
- 2 pts dropped out for AE not related to study drugs.

Table 2. Overview of AEs

verview of AEs (%) of pts	Cohort A mGC PDL-1 CPS ≥5	Cohort B mGC PDL-1 CPS <5	Cohort C mBiliary/pancreatic cancer	Overall (N=27)
	(n=9)	(n=9)	(N=9)	
rade (G) ≥3 AEs	2 (22%)	3 (33%)	1 (11%)	6 (22%)
orbipiprant-related G≥3 AEs	0	0	0	0
alstilimab-related G≥3 AEs	1 (11%)	1 (11%)	1 (11%)	3 (11%)
AEs	3 (33%)	1 (11%)	1 (11%)	5 (19%)
orbipiprant-related SAEs	0	0	0	0
alstilimab-related SAEs	0	0	1 (11%)	1 (4%)
Es leading to drop out	1 (11%)	1 (11%)	0	2 (7%)

Patient disposition

- each cohort.

- respectively.

Efficacy

- The primary endpoint in gastric cancer pts was met, with a 44% DCR and no safety issues. In cohort A, 3 pts had a partial response (PR), 2 of them still ongoing and all lasting more than 6 months; in addition, 1 pt had stable disease (SD). In cohort B, 4 pts had SD, 2 of them lasting more than 6 months. Lastly, in cohort C, 1 pt with pancreatic cancer had a PR, lasting 7 months and 1 BTC patient had SD.
- For GC pts, at a median follow-up of 6.8 months, the median PFS and OS were 2.0 and 9,7 months respectively, while in cohort C, at a median follow-up of 5.7 months, the median PFS and OS were 2.0 and 10,2 months respectively.
- Responses in GC occurred irrespective of MSI/MMR status and prior exposure to ICIs.
- Translational analyses on tissue and blood biomarkers are ongoing.

Table 3. DCR/ORR and PFS/OS

Best overall esponse, n (%)	Cohort A mGC PDL-1 CPS ≥5 (n=9)	Cohort B mGC PDL-1 CPS <5 (n=9)	Overall mGC (N=18)	Cohort C mBiliary/pancreatic cancer (N=9)
CR	0	0	0	0
PR	3 (33%)	0	3 (17%)	1 (11%)
SD	1 (11%)	4 (44%)	5 (28%)	1 (11%)
PD	5 (56%)	5 (56%)	10 (56%)	7 (78%)
DCR (CR+PR+SD), %	44%	44%	44%	22%
ORR (CR+PR), %	33%	0%	17%	11%
PFS median (95% CI)	2.0 (1.0-8.6)	1.8 (0.8-9.3)	2.0 (1.8-4.5)	2,0 (1.8-NR)
OS median (95% CI)	9.7 (2.4-NR)	6.8 (2.0-NR)	9.7 (4.3-NR)	10.2 (4.0-NR)
FU median (IQR)	8.3 (4.0-9.7)	6.8 (3.7-14.1)	6.8 (4.0-11.5)	5.7 (4.3-10.2)

Enrolment is completed. 27 pts were treated with vorbipiprant 90 mg bid in combination with an immune checkpoint inhibitor (ICI), 9 patients in


 25 pts discontinued treatment (23 for disease progression and 2 for AE) and 2 pts were still on treatment after 10 and 15 months.


 Overall, median age was 61 (IQR: 55-68) years, similar among cohorts; 70% were men, with a slightly higher prevalence in Cohort A


• The median number of prior treatment lines was 3 (IQR: 2-4) overall and in gastric cohorts, and 2 (IQR: 2-3) in other GI cancers cohort.

Prior ICIs were administered in 44%, 22% and 11% in Cohort A, B and C,

Microsatellite status was stable for the majority of patients.









#2608

e-mail Author: Filippo.Pietrantonio@istitutotumori.mi.i